---
layout: post
title: 'New Drug Approvals 2012 - Pt. XXX - Crofelemer (Fulyzaq TM) '
date: '2013-01-06T03:02:00.001Z'
author: felix
tags:
- Natural Product Drugs
- First-in-class Drugs
- Topical Drugs
- 2012 New Drugs
modified_time: '2013-01-06T03:02:22.913Z'
thumbnail: http://2.bp.blogspot.com/-eI-zkAciHhY/UObtQdgEfjI/AAAAAAAAAl8/afwQzV7mXHk/s72-c/ht_130102_fulyzaq_200x151.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4036008379551617621
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxx.html
---

<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-eI-zkAciHhY/UObtQdgEfjI/AAAAAAAAAl8/afwQzV7mXHk/s1600/ht_130102_fulyzaq_200x151.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-eI-zkAciHhY/UObtQdgEfjI/AAAAAAAAAl8/afwQzV7mXHk/s1600/ht_130102_fulyzaq_200x151.png" /></a></div>
<br />
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/7,0,1,0,0,1,1,0,0" width="400" /></center>
<br />
<div style="text-align: center;">
<b>ATC code:</b> not yet assigned</div>
<div style="text-align: center;">
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Crofelemer">Crofelemer</a></div>
<div style="text-align: center;">
<br /></div>
On December 31 2012, the FDA approved Crofelemer for the treatment of <a href="http://en.wikipedia.org/wiki/Diarrhea">diarrhea</a> caused by antiretroviral medication regimens taken by patients with <a href="http://en.wikipedia.org/wiki/HIV/AIDS">HIV/AIDS</a>.<br />
<br />
Diarrhea is a frequent <a href="http://hivinsite.ucsf.edu/insite?page=ar-05-01">adverse effect of antiretroviral medication</a> - however, it can also be caused by secondary infections of the gastrointestinal tract or the virus itself. The loss of fluids incurred by diarrhea can lead to dehydration and electrolyte imbalance. As a side-effect of antiretroviral medication it also reduces patient <a href="http://en.wikipedia.org/wiki/Compliance_%28medicine%29">compliance</a> with a prescribed medication regimen.<br />
<br />
<a href="http://en.wikipedia.org/wiki/Crofelemer">Crofelemer</a> alleviates the symptoms of HIV-associated diarrhea by limiting the amount of chloride ions that are pumped into the intestinal lumen, thus also retaining sodium ions and water. Crofelemer is a natural product oligomer that is not orally bioavailable but acts locally on the intestinal surface. It <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802429/">was shown</a> to inhibit two distinct intestinal chloride channels expressed in the luminal membrane of gut epithelial cells. One of them, the cystic fibrosis transmembrane conductance regulator (CFTR, Uniprot: <a href="http://www.uniprot.org/uniprot/P13569">P13569</a>, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL4051">CHEMBL4051</a>) is a member of the ABS transporter family, the other is a calcium-activated chloride channel (CaCC) and is called Anoctamin-1 (TMEM16A, Uniprot: <a href="http://www.uniprot.org/uniprot/Q5XXA6">Q5XXA6</a>). Anoctamin-1 is currently the only known CaCC expressed at the luminal membrane of gut epithelial cells but crofelemer might also inhibit other CaCCs. <br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-k7BlsNF7FUU/UObruU0Gj2I/AAAAAAAAAlo/bVgcW4T8YOE/s1600/crofelemer.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://2.bp.blogspot.com/-k7BlsNF7FUU/UObruU0Gj2I/AAAAAAAAAlo/bVgcW4T8YOE/s320/crofelemer.png" width="316" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<br />
Crofelemer is extracted from the red latex of the South American tree <a href="http://en.wikipedia.org/wiki/Croton_lechleri">Croton lechleri</a> and is an amorphous red-brown powder. The oligomer is a random sequence of <a href="http://www.ebi.ac.uk/chebi/searchId.do;F6C246F77375ECA4824466F8E26B0DF7?chebiId=CHEBI:15600">(+)-catechin</a>, (-)-epicatechin, <a href="http://www.ebi.ac.uk/chebi/searchId.do;D0DDCB8F858A298B94FF6575569C8634?chebiId=CHEBI:31018">(+)gallocatechin</a> and <a href="http://www.ebi.ac.uk/chebi/searchId.do;40BFF80A8830C6BFD572CB537C4FC412?chebiId=CHEBI:71227">(-)-epigallocatechin</a> monomers (on average 5 to7.5) and average mass of 1500Da to 2300Da. <br />
<br />
Crofelemer is dosed twice-daily in delayed release tablets containing 125mg of the active ingredient. It is practically not absorbed into the blood and typical pharmacokinetic parameters are thus not applicable.<br />
<br />
Crofelemer was initially developed by Shaman Pharmaceuticals and then continued by Napo Pharmaceuticals (Forbes has a <a href="http://www.forbes.com/forbes/2011/0117/entrepeneurs-pharma-prescriptions-lisa-conte-mission-impossible.html">short article</a> on Crofelemer's development). At the moment, <a href="http://www.salix.com/index.aspx">Salix Pharmaceuticals</a> holds a license for marketing in Japan, North America and Europe while <a href="http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN">Glenmark Pharmaceuticals</a> has exclusive rights to marketing in 140 developing countries including India (but excluding China).<br />
<br />
The commercial name for crofelemer is <a href="http://www.fulyzaq.com/">Fulyzaq</a>.<br />
<br />
<br />